tbuckley/cabot-search huggingface dataset:
A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.
Authors: Antonio Palumbo, Michele Cavo, Sara Bringhen, Maide Cavalli, Francesca Patriarca, Davide Rossi, Paola Tacchetti, Norbert Pescosta, Claudia Crippa, Monica Galli, Tonino Spadano, Angelo Michele Carella, Tommaso Caravita, Claudia Cellini, Antonio Ledda, Francesco Pisani, Jacopo Peccatori, Francesca Elice, Andrea Nozza, Valerio De Stefano, Luca De Rosa, Anna Marina Liberati, Fabrizio Ciambelli, Giovanni De Sabbata, Lucio Catalano, Alessandra Larocca, Fortunato Morabito, Elena Zamagni, Massimo Offidani, Patrizia Tosi, Mario Boccadoro
Journal: Blood (2009)
Pattern of Relapse and Progression After Autologous Stem-Cell Transplantation As Upfront Treatment for Multiple Myeloma
Authors: Carlos Fernández de Larrea, Raquel Jiménez, Laura Rosiñol, Eva Giné, Natalia Tovar, María Teresa Cibeira, Francesc Fernandez-Avilés, Carmen Martinez, Montserrat Rovira, Joan Blade
Journal: Blood (2012)
A phase I study to determine the effect of regorafenib (REG) on the pharmacokinetics (PK) of substrates of P-glycoprotein (P-gp; digoxin) and breast cancer resistant protein (BCRP; rosuvastatin) in patients with advanced solid tumors
Authors: D. Strumberg, S.-E. Al-Batran, I. Takacs, L. Géczi, A. Cleton, F. Huang, U. Mueller, K. Graudenz, Z. Trnkova, I. Sturm
Journal: Annals of Oncology (2016)
OS5.6 Initial treatment strategy for presumed low-grade glioma: a preoperative perspective
Authors: M. M. J. Wijnenga, T. Mattni, P. J. French, G. J. Rutten, S. Leenstra, F. Kloet, M. J. B. Taphoorn, M. J. van den Bent, M. L. C. van Veelen, A. J. P. E. Vincent
Journal: Neuro-Oncology (2016)
NIMG-59. MAGNETIC RESONANCE IMAGING SEQUENCE ARTERIAL SPIN LABELING (ASL) IN THE MONITORING OF PATIENTS WITH GLIOMA: AN AID IN DETERMINING PROGRESSION VS. TREATMENT CHANGE
Authors: Pamela New, Steven Fung
Journal: Neuro-Oncology (2016)

The evaluation and follow-up of patients with high grade glioma undergoing treatment continues to be a challenge. Glioblastoma is a highly vascular tumor and there is a need to assess angiogenesis in the course of treatment as response is monitored. ASL is a noninvasive perfusion imaging method which uses blood water as an infusible endogenous tracer. Serial MRI with ASL of 13 patients with treated glioma followed longitudinally over time were reviewed. There were 7 cases of glioblastoma, 2 anaplastic astrocytomas, 1 optic glioma, 2 low grade oligodendrogliomas, and 1 low grade astrocytoma. All patients were followed by serial brain MRI, including ASL using 3D pCASL (pseudo-continuous ASL) obtained prior to gadolinium contrast administration. CBF maps (in ml/100gm/min.) were created from ASL data, and maximum CBF measurements were recorded and correlated to enhancing and non-enhancing regions of treated glioma. Elevated CBF values correlated with tumor progression and at times ante-dated changes seen on contrast-enhanced MRI or FLAIR. These regions of increased CBF were typically surrounded by a halo of relatively decreased CBF, probably background of treated tumor. Bland regions of relatively low CBF correlated with treatment effect when contrast-enhanced images suggested tumor progression. Increased CBF from a seizure focus in peri-ictal state can be misinterpreted as tumor progression. ASL is an emerging MRI technique that provides quantitative CBF measurements without contrast administration, ideal for following patients diagnosed with high grade glioma undergoing treatment. It may be helpful in the setting of a patient with suspicious progression on contrast MRI and fluid attenuated inversion recovery (FLAIR) sequences and no neurological progression, for whom treatment decisions need to be made.
MeCP2 mutations: progress towards understanding and treating Rett syndrome
Authors: Ruth R. Shah, Adrian P. Bird
Journal: Genome Medicine (2017)

Rett syndrome is a profound neurological disorder caused by mutations in the MECP2 gene, but preclinical research has indicated that it is potentially treatable. Progress towards this goal depends on the development of increasingly relevant model systems and on our improving knowledge of MeCP2 function in the brain.
Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.
Authors: Christian Baumgartner, Karoline V. Gleixner, Alexander Gruze, Puchit Samorapoompichit, Harald Esterbauer, Winfried F. Pickl, Christian Sillaber, Peter Valent
Journal: Blood (2007)
The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen
Authors: Anna Panovska, Daniel Lysák, Lukas Smolej, Yvona Brychtova, Martin Simkovic, Monika Motyckova, Michaela Lindtnerova, Martin Trbusek, Jitka Malcikova, Sarka Pospisilova, Jiri Mayer, Michael Doubek
Journal: Blood (2012)
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial
Authors: Sudarshan Paramsothy, Michael A Kamm, Nadeem O Kaakoush, Alissa J Walsh, Johan van den Bogaerde, Douglas Samuel, Rupert W L Leong, Susan Connor, Watson Ng, Ramesh Paramsothy, Wei Xuan, Enmoore Lin, Hazel M Mitchell, Thomas J Borody
Journal: The Lancet (2017)
Young age is not always an adverse prognostic factor in breast cancer
Authors: M. A. Seoud, M. Khalil, N. El- Saghir, Z. Salem, M. Charafeddine, J. Abbas, M. Sidani, A. Shamseddine
Journal: Journal of Clinical Oncology (2005)

825 Background: This is a survival analysis of Lebanese women with breast cancer treated at AUBMC between 1990 and 2001 Methods: Charts of all breast cancer patients (pts) treated at AUBMC between 1990 and 2001 were retrospectively reviewed. Chart information was completed by telephone interviews. Patients were divided into three groups: Below 35 years (group 1), 35–50 years (Group 2), and above 50 years (Group 3). Data was analyzed using SPSS, Chi-square, Cox regression analysis, and Kaplan Meier. p<0.05 was considered as significant. Results: There were a total of 1320 pts of whom 823 had a complete follow up. Mean age at presentation 50.8 ± 12.2 years. Only 56% of the patients were postmenopausal. Mean follow-up time was 42 ± 35 months. Age distribution was as follows: 108 pts (8.1%) in group 1, 526 pts (39.9%) in group 2 and 686 pts (52%) in group 3. Distribution of the stage at presentation among these groups was not statistically different p=0.653. Hormone receptor status (ER and/or PR) was not statistically different between the 3 groups with p value of 0.259. Group 1: 67.9%, group 2: 63%, and group 3: 68.7% had positive receptors. 73.6% of Group 1 pts received chemotherapy compared to 70.6% and 50.8% in groups 2 and 3 respectively (p<0.001), whereas 77.4% of hormone positive group 3 pts received hormonal therapy compared to 63.2% and 69% of groups 1 and 2 respectively (p<0.001). Five-year survival for hormone positive patients was 86.4% compared to only 69.6% for hormone negative pts (p<0.001). Kaplan-Meier 5-year projected survival by stage was not influenced by age. It was 72.5%, 79% and 80% in groups 1, 2 and 3 respectively. (p= 0.15). Univariate analysis showed that higher number of positive lymph nodes (LNs), negative hormonal receptors, higher grade, and bigger tumor size were predictors of death irrespective of the age group, and adjuvant treatment. Multivariate analysis showed that only the number of positive LNs, and hormonal status were predictors of death which was also independent of the age group. Conclusions: In our population, the survival of young patients with breast cancer is similar to older patients. This may be related to a higher percentage of receptor positive patients No significant financial relationships to disclose.
B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.
Authors: Michele Dal-Bo, Paola Secchiero, Massimo Degan, Riccardo Bomben, Dania Benedetti, Antonella Zucchetto, Daniela Marconi, Gabriele Pozzato, Gianluca Gaidano, Giovanni Del Poeta, Francesco Forconi, Giorgio Zauli, Valter Gattei
Journal: Blood (2009)
A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments
Authors: Brian A Walker, Shweta S. Chavan, Jie He, Ruslana Tytarenko, Shan Zhong, Shayu Deshpande, Purvi Patel, Caleb K. Stein, Owen W Stephens, Niels Weinhold, Nathan Petty, Doug Steward, Carolina Schinke, Leo Rasche, Mark Bailey, Siraj Ali, Jo-Anne Vergillo, Jeff Ross, Vincent A. Miller, Phillip J Stephens, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Tariq I Mughal, Faith E Davies, Gareth J Morgan
Journal: Blood (2016)
Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
Authors: M. Sznol, P.F. Ferrucci, D. Hogg, M. Atkins, P. Wolter, M. Guidoboni, C. Lebbe, J. Kirkwood, J. Schachter, G. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, J. Jiang, F.S. Hodi, J. Wolchok
Journal: Annals of Oncology (2016)
PALL-02. THE IMPACT AND VALUE OF INTEGRATING PALLIATIVE CARE INTO A NEURO-ONCOLOGY CLINIC
Authors: Matthew Manning, Mary Larach
Journal: Neuro-Oncology (2016)

Palliative care in oncology enhances symptom management and improves survival. As reimbursement shifts from fee for service to value based population health, this study measures the impact of adding a palliative care provider (PCP) in neuro-oncology. Over six months, a palliative nurse practitioner was integrated into a weekly multidisciplinary brain and spine oncology clinic. The provider participated in the conference reviewing recent MRIs and discussing current disease status and treatment options. The PCP would consult on up to four of the clinic patients. Data were recorded regarding patient characteristics, goals of care, and changes in therapy. Of the cases who met with the palliative provider for formal consultation, the most common diagnoses were 41.6% with metastatic lung cancer and 25% with glioblastoma. For goals of care, an Advanced Directive discussion was documented in 100%. Do Not Resuscitate (DNR) orders were activated in 37.5% and documented in 54%. Medical Orders for Scope of Treatment (MOST) forms were introduced in 87.5% and completed in 25%. For changes in therapy, enrollment in hospice occurred in 33.3%. Pain medication was changed in 33.3%. Other symptoms including fatigue, weakness, anorexia, constipation, anxiety, lymphedema, dysphagia, depression, insomnia, and alopecia were managed in 87.5%. Using accepted cost savings models, $72,000 was saved due to hospice enrollment and $110,400 was saved by consulting palliative care yielding an anticipated annual savings of $364,800 to the population by adding a 0.1 FTE to the clinic. This study suggests that a PCP in neuro-oncology can produce a high rate of establishing goals of care. A PCP can significantly reduce the cost of care in a value based model. Further study on the impact of palliative care in neuro-oncology seems warranted.
Long-Term Efficacy and Safety of Low-Molecular-Weight Heparins (LMWH) for Cancer-Associated Venous Thromboembolism (VTE) in Tropique, a Prospective Non-Interventional Observational Study
Authors: Dominique Farge, Philippe Debourdeau, Norbert Claude Gorin, Anne Lamblin, Francis Cajfinger
Journal: Blood (2014)
Denosumab in patients with bone metastases from renal-cell carcinoma treated with anti-angiogenic therapy: a retrospective study from the GETUG (Groupe Etude des Tumeurs Uro Genitales)
Authors: A. Guillot, C. Joly, P. Barthelemy, E. Meriaux, S. Negrier, D. Pouessel, C. Chevreau, H. Mahammedi, N. Houede, G. Roubaud, G. Gravis, S. Tartas, L. Albiges, C. Vassal, M. Oriol, F. Tinquaut, S. Espenel, S. Culine, K. Fizazi
Journal: Annals of Oncology (2016)
Phase II study of carboplatin/pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A)
Authors: Eisaku Miyauchi, Kazuhiro Usui, Shunichi Sugawara, Masaru Nishitsuji, Yuka Fujita, Atsuto Mouri, Hiroshi Watanabe, Hiroshi Sakai, Ichiro Kinoshita, Koichi Hagiwara
Journal: Annals of Oncology (2016)
IGFBP7 Gene Promoting Cell Proliferation in Acute Myeloid Leukemia Through Activation of AKT3 and CCND1
Authors: Shaoyan Hu, Shui-yan Wu, Jian-nong Cen, Jian Pan, Xiaofei Qi, Zixing Chen, Xing Feng, Chien-Shing Chen
Journal: Blood (2012)
Four-Factor Prothrombin Complex Concentrate (4F-PCC) Effectively Reverses Rivaroxaban Induced Bleeding in a Rabbit Model of Acute Bleeding
Authors: Eva Herzog, Jochen Mueller-Cohrs, Franz Kaspereit, Wilfried Krege, Peter Niebl, Baerbel Doerr, Stefan Schulte, Gerhard Dickneite
Journal: Blood (2014)
GENT-42. SIMULTANEOUS MEASUREMENT OF MGMT METHYLATION AND DETERMINATION OF IDH1 R132H AND CpG ISLAND METHYLATOR PHENOTYPE (CIMP) IN GLIOMAS USING COUPLED ABSCRIPTION PCR SIGNALING (CAPS)
Authors: David McCarthy, Oscar Diago, Daniel Hogan, Derek Ostertag, Michelle Hanna
Journal: Neuro-Oncology (2016)

Tumor samples received by clinical laboratories often contain insufficient amplifiable DNA to measure gene-specific DNA methylation for even a single target, such as MGMT, with bisulfite or MSRE based methods, due to lack of sensitivity. For this reason, multi-gene DNA methylation tests, such as the eight gene Glioma CpG Island Methylator Phenotype (G-CIMP), have not been successfully transferred to the clinical lab. In order to simultaneously determine MGMT methylation status, G-CIMP, and the presence of the IDH1 R132H mutation, even in challenging samples of low concentration or damaged DNA, a new detection method, Coupled Abscription PCR Signaling (CAPS), was developed. Samples from 26 of the patients with recurrent high grade glioma participating in Tocagen’s Phase 1 trial (NCT01470794) were analyzed using CAPS to (1) measure methylation of the MGMT promoter, (2) measure methylation of a streamlined three gene panel to determine the G-CIMP, and (3) probe for the presence of the IDH1 R132H mutation. IDH1 R132H status was also determined by sequencing. In 26/26 samples, results obtained for IDH1 R132H with CAPS matched sequencing results. In 25/26 samples, CIMP status obtained from the three gene methylation panel correlated with the IDH1 R132H status. In a single case, both CAPS and sequencing scored negatively for the IDH1 R132H mutation, but the tumor was clearly CIMP+ based on DNA methylation analysis. Additional sequencing is underway to determine if this tumor contains a different mutation in IDH1 or a mutation in IDH2, which can also cause CIMP+. CAPS based detection and a simpler three gene CIMP panel make it possible to now determine both CIMP/IDH1 R132H and MGMT methylation, even when only limited FFPE tumor material is available for testing. Together, this MGMT/CIMP/IDH1 diagnostic increases the applicability and reliability for prognostic assessment of patients diagnosed with brain cancer compared to currently available assays.
Sulfated Colominic Acid Enhances CXCR4 Function and Promotes Hematopoietic Stem /Progenitor Egress from Bone Marrow.
Authors: Shiro Kubonishi, Yoshio Katayama, Shinya Yamaguchi, Hirokazu Tamamura, Nobutaka Fujii, Takeshi Watanabe, Fernando Arenzana-Seisdedos, Kazuma Ikeda, Mitsune Tanimoto
Journal: Blood (2005)
genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
Authors: A. Ravaud, R.J. Motzer, H.S. Pandha, M. Staehler, D. George, A.J. Pantuck, A. Patel, Y.-H. Chang, B. Escudier, F. Donskov, A. Magheli, G. Carteni, B. Laguerre, P. Tomczak, J. Breza, P. Gerletti, X. Lin, M. Lechuga, J.-F. Martini, J.-J. Patard
Journal: Annals of Oncology (2016)
P06.05 Myoinositol as a predictive baseline biomarker for overall survival of patients with recurrent glioblastoma treated with Bevacizumab: A 1H-magnetic resonance spectroscopy study.
Authors: E. Steidl, U. Pilatus, J. P. Steinbach, F. Zanella, M. W. Ronellenfitsch, E. Hattingen, O. Bähr
Journal: Neuro-Oncology (2016)
Distribution of KIR2DS4 Alleles in Chinese Han Population and the Impact of KIR2DS4 Alleles On the Development of Acute Gvhd Post Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Xiaojing Bao, Lihua Hou, Aining Sun, Qiaocheng Qiu, Xiaoni Yuan, Minghua Chen, Jun He
Journal: Blood (2009)
Corrigendum: Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4
Authors: Pilar Ramos, Anthony N Karnezis, David W Craig, Aleksander Sekulic, Megan L Russel, William P D Hendricks, Jason J Corneveaux, Michael T Barrett, Karey Shumansky, Yidong Yang, Sohrab P Shah, Leah M Prentice, Marco A Marra, Jeffrey Kiefer, Victoria L Zismann, Troy A McEachron, Bodour Salhia, Jaime Prat, Emanuela D'Angelo, Blaise A Clarke, Joseph G Pressey, John H Farley, Stephen P Anthony, Richard B S Roden, Heather E Cunliffe, David G Huntsman, Jeffrey M Trent
Journal: Nature Genetics (2014)
Unrelated Allogeneic Stem Cell Transplantation with Myeloablative Conditioning in Adults with Acute Lymphoblastic Leukemia in Remission: Peripheral Blood or Bone Marrow?.
Authors: Nadezda Basara, Myriam Labopin, Tapani Ruutu, Axel Zander, Oliver Ottmann, Renate Arnold, Vanderson Rocha
Journal: Blood (2007)
Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL)
Authors: John J. Powers, Kamira K. Maharaj, Eva Sahakian, Limin Xing, Patricio PerezVillarroel, Tessa Knox, Steven Quayle, Simon S Jones, Alejandro Villagra, Eduardo M. Sotomayor, Javier Pinilla-Ibarz
Journal: Blood (2014)
CSIG-10. SHH-MEDULLOBLASTOMA PREFERENTIALLY ARISES FROM GRANULE CELL PRECURSORS IN THE LATERAL CEREBELLUM
Authors: I-Li Tan, Alexandre Wojcinski, Harikrishna Rallapalli, Eugenia Volkova, Marc Remke, Andrey Korshunov, Daniel Turnbull, Michael Taylor, Alexandra Joyner
Journal: Neuro-Oncology (2016)

The cerebellar tumor Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Aggressive treatments including surgery, radiotherapy and chemotherapy for these young patients can greatly affect their motor control and cognitive and social behaviors controlled by the cerebellum. Mechanistic studies of MB progression are urgently needed in order to develop less toxic targeted therapies. MB is divided into four subgroups: WNT, SHH, Group 3 and Group 4. SHH-MB comprises 30% of all MBs and the main cell type of origin is granule cell progenitors (GCPs), which comprise a transient amplifying population in the developing cerebellum regulated by SHH signaling. We utilized inducible recombinases to overexpress a constitutively active form of SMO (SmoM2) or delete Ptch1 in few GCPs at Postnatal (P) day 2. Interestingly, we found that 200 SmoM2 mutant cells are sufficient to generate tumors and all tumors develop only in the lateral cerebellum (hemispheres). This finding correlates with MRI studies showing that SHH-MB subgroup patients have tumors preferentially in the hemispheres, whereas the other subgroups are found almost exclusively in the midline (vermis). We hypothesized that SHH-MB arises mainly in the hemispheres because GCPs are intrinsically different in this location. By using a mosaic analysis to test whether susceptibility to hyperactivation of the SHH pathway is regionally regulated, we discovered that Ptch1/SmoM2 mutant GCPs in the hemispheres indeed differentiate less compared to the vermis. Microarray analysis of P8 GCPs and P21 pre-neoplastic lesions revealed subsets of genes that are differentially expressed between the vermis and hemispheres, and between the two stages. We are validating candidate genes that could contribute to tumorigenesis. Our studies should provide new insights into the cellular and genetic mechanisms underlying SHH-MB progression, and to the identification of novel drug targets to aid in development of new therapies for this childhood tumor.
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
Authors: J.H. Lee, G.V. Long, S. Boyd, S. Lo, A.M. Menzies, V. Tembe, A. Guminski, V. Jakrot, R.A. Scolyer, G.J. Mann, R.F. Kefford, M.S. Carlino, H. Rizos
Journal: Annals of Oncology (2017)
IMST-02. TRANSGENIC EXPRESSION OF IL15 IMPROVES ANTIGLIOMA ACTIVITY OF IL13Rα2-CAR T CELLS BUT HIGHLIGHTS THE NEED TO TARGET MULTIPLE GLIOMA-ASSOCIATED ANTIGENS
Authors: Giedre Krenciute, Irina Balyasnikova, Gianpietro Dotti, Stephen Gottschalk
Journal: Neuro-Oncology (2016)

The goal of this project is to develop T cells expressing IL13Rα2-specific chimeric antigen receptor (CAR) as an effective immunotherapy for glioblastoma (GBM), the most aggressive, primary brain tumor in humans, in which outcome remains poor. We recently demonstrated that IL13Rα2-CARs with a CD28.z endodomain had potent anti-GBM activity in preclinical models. However, IL13Rα2-CAR T-cell persistence was limited, resulting in recurrence of IL13Rα2-positive GBMs. Next we wanted to evaluate if transgenic expression of IL-15 enhances persistence and anti-tumor activity of IL13Rα2-CAR.CD28.ζ T cells. We generated IL13Rα2-CAR.CD28.ζ T cells expressing IL-15 (IL13Rα2-CAR.IL15 T cells) and determined the effector function of IL13Rα2-CAR.IL15 T cells in vitro and in vivo. Double transduction of CD3/CD28-activated T cells resulted in T-cell lines that expressed both transgenes in 45-50% of T cells. At base line IL13Rα2-CAR.IL15 T cells produced on average 69.5 pg/ml of IL15. Production was significantly increased after CD3 or antigen-specific T-cell stimulation (176.7 pg/ml; n=6; p<0.001). IL13Rα2-CAR.IL15 T cells were as efficient as IL13Rα2-CAR T cells in killing IL13Rα2-positive GBMs in vitro. After intratumoral injection into U373 glioma-bearing mice IL13Rα2-CAR.IL15 T cells persisted significantly longer than IL13Rα2-CAR T cells (p<0.05). This resulted in a significant increase in progression free (84 vs 49 days; p=0.008) and overall survival (p=0.02) of treated mice. 3/5 examined, recurring U373 gliomas post IL13Rα2-CAR.IL15 T-cell therapy had down regulated IL13Rα2 expression, indicating immune escape. While all recurring GBMs expressed the glioma-associated antigen EphA2, 1/5 GBMs had also down regulated the expression of the glioma-associated antigen HER2. In conclusion, transgenic expression of IL15 enhances the in vivo persistence of IL13Rα2-CAR T cells resulting in improved anti-glioma activity. However, enhanced in vivo T-cell persistence resulted in the development of antigen-specific and -unspecific loss variants highlighting the need to target multiple glioma-associated antigens in tumors with heterogeneous antigen expression such as GBM.
Final Analysis of a Multicenter, Randomised Study Comparing Zoledronate vs Observation in Patients with Asymptomatic Myeloma.
Authors: Pellegrino Musto, Maria Teresa Petrucci, Sara Bringhen, Tommasina Guglielmelli, Tommaso Caravita, Enrico Balleari, Alessandro Andriani, Giovanni D’Arena, Velia Bongarzoni, Roberto Guariglia, Giuseppe Pietrantuono, Oreste Villani, Maria Carmen Martorelli, Fiorella D’Auria, Pasquale Niscola, Antonietta Falcone, Grazia Sanpaolo, Antonio Palumbo
Journal: Blood (2007)